论文部分内容阅读
目的：评价奥沙普秦肠溶片治疗类风湿关节炎的疗效和安全性。方法：多中心开放性临床试验８１２例类风湿关节炎病人（男性３１３例，女性４９９例，年龄４６ａ±ｓ１７ａ），每日口服奥沙普秦肠溶片２片（４００ｍｇ），４ｗｋ为一个疗程，连用２～４个疗程。结果：总有效率为７７．１％，不良反应发生率为９．０％，主要出现在胃肠道，程度轻微。结论：奥沙普秦肠溶片治疗类风湿关节炎，不良反应少且轻微，为长效的抗炎、镇痛药。
Objective: To evaluate the efficacy and safety of oxalipuen enteric-coated tablets in the treatment of rheumatoid arthritis. METHODS: A multicenter, open-label, clinical trial of 812 patients with rheumatoid arthritis (313 males and 499 females, age 46a ± s17a) was enrolled in this study. Oxycladine enteric-coated tablets (400 mg) were orally administered daily for 4 weeks, , Even with 2 to 4 courses. Results: The total effective rate was 77.1%, the incidence of adverse reactions was 9.0%, mainly in the gastrointestinal tract, to a lesser extent. Conclusion: Oxaproichin enteric-coated tablets for the treatment of rheumatoid arthritis, adverse reactions and minor, long-acting anti-inflammatory and analgesic drugs.